DRRX: DURECT Corporation Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 31.35
Enterprise Value ($M) 32.73
Book Value ($M) 1.22
Book Value / Share 0.04
Price / Book 25.76
NCAV ($M) -8.42
NCAV / Share -0.27
Price / NCAV -3.72

Profitability (mra)
Return on Invested Capital (ROIC) -1.14
Return on Assets (ROA) -0.31
Return on Equity (ROE) -1.18

Liquidity (mrq)
Quick Ratio 0.60
Current Ratio 0.71

Balance Sheet (mrq) ($M)
Current Assets 14.43
Assets 24.07
Liabilities 22.85
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
7 days ago 13G/A Asen R Scott 8.41 70.68
03-27 13G Ingalls & Snyder Llc 8.60 -66.81
02-14 13G/A Lion Point Capital, LP 0.00 -100.00
12-01 13G/A Bleichroeder LP 0.00 -100.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-25 8,095 95,626 8.47
2024-11-22 66,167 161,675 40.93
2024-11-21 3,105 101,012 3.07
2024-11-20 4,422 81,047 5.46

(click for more detail)

Similar Companies
DMAC – DiaMedica Therapeutics Inc. DNTH – Dianthus Therapeutics, Inc.
DRMA – Dermata Therapeutics, Inc. DRUG – Bright Minds Biosciences Inc.
DTIL – Precision BioSciences, Inc.


Financial data and stock pages provided by
Fintel.io